Skip to main content
OpenTrials
Completed

NCT Number: NCT00560508

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD on levodopa (L-DOPA) therapy (the double-blind period). The double-blind period will be followed by the open-label 52 week administration of pramipexole ER to evaluate the long term safety and efficacy (the open-label period).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

1 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

248.610.019 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients with diagnosis of PD including juvenile Parkinsonism, in whom the onset began at the age of forty or younger.
  • Patients with a modified Hoehn and Yahr scale of II to IV at "on" time.
  • Patients who have received an individual dosage of L-DOPA (either standard L-DOPA or L-DOPA with dopa-decarboxylase inhibitor) at a stable dose for at least 4 weeks before the baseline visit (Visit 2).
  • Patients who exhibit any therapeutically problematic issues or status based on L-DOPA therapy:
  • wearing-off phenomena
  • no on /delayed on
  • dystonia at off time
  • on-off phenomena
  • freezing phenomena at off time
  • the sub-optimal dose of L-DOPA had been administered due to side effects (such as dyskinesia), or therapeutical strategy

Exclusion criteria

  • Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
  • Dementia, as defined by a Mini-Mental State Examination (MMSE) score <24 at screening visit.
  • Any psychiatric disorder according to DSM-IV criteria that could prevent compliance or completion of the trial and/or put the patient at risk if he/she takes part in the trial.
  • History of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation in the trial would not represent a significant risk for the patient).
  • Clinically significant ECG abnormalities at screening visit, according to investigator's judgement.
  • Clinically significant hypotension or symptomatic orthostatic hypotension (i.e., clinical symptoms of orthostatic hypotension such as dizziness postural etc associated with a decline >=20 mmHg in systolic blood pressure and a decline >=10 mmHg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) either at screening visit or at baseline visit.
  • Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the trial.
  • Pregnancy (to be excluded by serum pregnancy test at screening visit) or breast-feeding.
  • Sexually active female of childbearing potential not using a medically approved method of birth control within one month before to the screening visit and throughout the trial period.
  • Serum levels of AST, ALT, alkaline phosphatases or bilirubin >2 upper limits of normal .
  • Patients with a creatinine clearance <50 mL/min
  • Patients with a complication or signs of malignant tumours or those within 5 years after the treatment.

Treatment and study plan

Pramipexole Immediate Release

Drug

titrated as individually needed (0.25 mg - 4.5 mg daily)

Pramipexole Extended Release

Drug

titration as individually needed (0.375 mg -4.5 mg daily)

Primary outcomes

  1. Percentage of Participants Who Experienced Adverse Events

    Time frame: 12 weeks

    An adverse event is defined as any untoward medical occurrence

Secondary outcomes

  1. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score

    Time frame: baseline and after 12 weeks treatment

    UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

  2. Change From Baseline in Percentage Off-time

    Time frame: baseline and after 12 weeks treatment

    Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

  3. Change From Baseline in Percentage On-time Without Dyskinesia

    Time frame: baseline and after 12 weeks treatment

    Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  4. Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia

    Time frame: baseline and after 12 weeks treatment

    Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  5. Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia

    Time frame: baseline and after 12 weeks treatment

    Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  6. Change From Baseline in Percentage On-time With Troublesome Dyskinesia

    Time frame: baseline and after 12 weeks treatment

    Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  7. Responder Rate For Clinical Global Impression of Improvement (CGI-I)

    Time frame: baseline and after 12 weeks treatment

    CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)

  8. Responder Rate For Patient Global Impression of Improvement (PGI-I)

    Time frame: baseline and after 12 weeks treatment

    PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring of 1 or 2 (at least much better)

  9. Change From Baseline in UPDRS Part I Score

    Time frame: baseline and after 12 weeks treatment

    UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood

  10. Change From Baseline in UPDRS Part II Score

    Time frame: baseline and after 12 weeks treatment

    UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.

  11. Change From Baseline in UPDRS Part III Score

    Time frame: baseline and after 12 weeks treatment

    UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms

  12. Change From Baseline in UPDRS Part IV Score

    Time frame: baseline and after 12 weeks treatment

    UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy

  13. UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)

    Time frame: baseline and after 12 weeks treatment

    Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse

  14. Change From Baseline in L-dopa Daily Dose

    Time frame: baseline and after 12 weeks treatment

    The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.

  15. Trough Plasma Concentration at Steady State

    Time frame: at Visit 8 after pramipexole ER 4.5mg and IR 4.5mg treatment

    Geometric mean (gMean) was calculated for trough plasma concentrations of pramipexole at steady state after administration of pramipexole IR 4.5mg and pramipexole ER 4.5mg.

  16. Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment

    Time frame: from Visit 1 to Visit 8 after pramipexole ER

    Dose proportionality of trough plasma concentrations at steady state is explored by using the power model that described the functional relationship between the dose and plasma concentration

  17. Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)

    Time frame: Week 12 to Week 16

    UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms. Least square means and standard errors presented are from ANCOVA with factors treatment and covariate baseline.

  18. Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)

    Time frame: Week 12 to Week 16

    Percentage of patients with no worsening of UPDRS Parts II+III Total Score by more than 15% from week 12 to week 16 (Open-label: Dose Adjustment Phase)

  19. Clinical Global Impression of Improvement (CGI-I) at Week 16 Compared to Patient's CGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)

    Time frame: Week 12 to Week 16

    Clinical Global Impression of Improvement (CGI-I) at week 16 compared to patient's CGI-I status at week 12. CGI-I scores ranging from '1' (very much improved) to '7' (very much worse)

  20. Patient Global Impression of Improvement (PGI-I) at Week 16 Compared to Patient's PGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)

    Time frame: Week 12 to Week 16

    Patient Global Impression of Improvement (PGI-I) at week 16 compared to patient's PGI-I status at week 12. PGI-I scores ranging from '1' (very much better) to '7' (very much worse).

  21. Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)

    Time frame: Baseline and after 64 weeks treatment

    UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

  22. UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse

  23. Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

  24. Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  25. Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  26. Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  27. Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  28. Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.

  29. Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood

  30. Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.

  31. Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms

  32. Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)

    Time frame: baseline and after 64 weeks treatment

    UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER

Important dates

Study start
2007
Primary completion
2009
First posted
Nov 19, 2007
Registry last updated
Jul 31, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.